About
Dr Anwar Alam was awarded his Ph.D degree from Jawaharlal Nehru University, New Delhi. He has more than 10 years of experience in research post-PhD and 4 years in academic teaching. His area of specialization is Nanoparticle based drug-targeting and Infectious biology. He earlier worked as project Scientist at the ICMR-National Institute of Pathology (ICMR-NIP) and Department of Biochemical Engineering & Biotechnology, IIT-Delhi. He was a member of ICMR-NIP core team for COVID-19 management, where he played key role in establishing central depot for disbursement for COVID-19 kits across India, established labs for sample testing and kit validation. For his exemplary work during COVID-19 pandemic, he was awarded the “COVID warrior” by the ICMR-NIP. He has been the team member in projects funded by DBT, DST and ICMR; and successfully completed four projects. The main thrust of research in these projects were to explore the epidemiology and multi-drug resistance of Tuberculosis using Next-generation Sequencing, develop new chemical entities including drug-repurposing and host directed therapies for Tuberculosis (TB). He is part of team that has developed a first-in class drug to target latent TB bacilli. He is currently leading a team of researchers including post-doc Scientists in three extramural projects on Development of Biomarker for screening TB, AI ML based prediction of multi-drug resistance and testing of a low-cost field deployable tool for TB detection. He has filed several more than 7 patents that includes medicaments for treatment of infections caused by biofilm forming pathogens and recombinant multi-epitope vaccines.